


Klaus Buchholz, John Collins

 WILEY-VCH

Concepts in Biotechnology

History, Science and Business



*Klaus Buchholz and
John Collins*

Concepts in Biotechnology

Related Titles

Nicolaou, K. C., Montagnon, T.

Molecules that Changed the World

385 pages

2008

Hardcover

ISBN: 978-3-527-30983-2

Sneader, W.

Drug Discovery

A History

472 pages

Softcover

ISBN: 978-0-471-89980-8

Ho, R. J. Y., Gibaldi, M.

Biotechnology and Biopharmaceuticals

Transforming Proteins and Genes into Drugs

576 pages

2003

Softcover

ISBN: 978-0-471-20690-3

Greenberg, A.

The Art of Chemistry

Myths, Medicines, and Materials

384 pages

2003

Hardcover

ISBN: 978-0-471-07180-8

Sapienza, A. M., Stork, D.

Leading Biotechnology Alliances

Right from the Start

216 pages

2001

Hardcover

ISBN: 978-0-471-18248-1

Klaus Buchholz and John Collins

Concepts in Biotechnology

History, Science and Business



WILEY-VCH Verlag GmbH & Co. KGaA

The Authors

Prof. em. Dr. Klaus Buchholz

Technical University Braunschweig
Institute for Chemical Engineering
Hans-Sommer-Str. 10
38106 Braunschweig
Germany

Prof. em. Dr. John Collins

Technical University Braunschweig
Life Sciences Faculty
c/o Helmholtz Centre for Infection Research – HZI
AG Directed Evolution
Inhoffenstr. 7
38124 Braunschweig
Germany

All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2010 WILEY-VCH Verlag & Co. KGaA,
Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Cover Illustration:

Production fermenters with kind permission by Roche Penzberg, Germany

Cover Adam Design, Weinheim

Typesetting Thomson Digital, Noida, India

Printing and Binding betz-druck GmbH, Darmstadt

Printed in the Federal Republic of Germany
Printed on acid-free paper

ISBN: 978-3-527-31766-0

For

Diana and Marie-Christianne

Contents

Preface *XVII*

Abbreviations and Glossary *XXI*

Part One History 1

1 Introduction 3

2 The Early Period to 1850 5

2.1 Introduction 5

2.2 Experimental Scientific Findings 8

2.2.1 Alcoholic Fermentation 8

2.2.2 'Unformed, Unorganized Ferments' 11

2.3 Application 12

2.3.1 Education 15

2.4 Theoretical Approaches 16

2.4.1 The School of Vitalism 17

2.4.2 The Chemical School 20

2.4.3 History of Science Approaches: Preparadigmatic Research;
Fermentation – An Epistemic Thing 21
References 24

3 The Period from 1850 to 1890 27

3.1 Introduction 27

3.2 Experimental Findings 27

3.2.1 Fermentation – Definite Results by Pasteur 27

3.2.2 'Unformed, Soluble Ferments' – Enzymatic Reactions 35

3.3 Practical Application, Technical Progress and Institutional
Development 35

3.3.1 Products and Progress in Processes 35

3.3.2 Application Research, Bacteriology, and New Institutions 40

3.4 Theoretical Approaches 41

3.4.1 Fermentation Theory, an Epistemic Thing 41

3.4.2	Pasteur Establishes a New Paradigm	42
3.4.3	The Question of Living and Unformed Ferments (Enzymes), and Explanatory Concepts	45
	References	47
4	The Period from 1890 to 1950	51
4.1	Introduction	51
4.2	Research – Advances in the Basics of Biotechnology. Experimental Findings	51
4.2.1	Biochemistry	51
4.2.2	Microbiology	59
4.2.3	The Case of Penicillin – the Beginning of the Antibiotics Era	62
4.3	Technological Development, Progress and Application	64
4.3.1	Expanding Enzyme Technology	64
4.3.2	Wartime Production, First World War: Acetone, Butanol, Glycerol	65
4.3.3	New Fermentation Products: Citric Acid, Fermented Food, Enzymes; Waste Water Treatment	68
4.3.4	War Requirements of the Second World War: Penicillin Production – A New Quality of Technology	70
4.4	Theoretical Approaches	76
4.4.1	The Biochemical Paradigm, and the New Discipline of Biochemistry	76
4.4.2	Microbiology – Normal, Postparadigmatic Science	81
4.4.3	Influences External to Science: War Requirements – the Case of Penicillin	83
	References	84
5	Outlook, from 1950 Onwards: Biotechnology – Science or What?	89
5.1	Introduction	89
5.2	Traditional Biotechnology and the Dechema Report	90
5.2.1	Traditional Products	90
5.2.2	Political Initiatives: The Dechema Report	90
5.2.3	The Scientific Status of Biotechnology up to the 1970s	92
5.3	The Changing Focus in BT in the USA in the Early 1980s	93
5.3.1	The Role of Politics in the USA: The OTA Study, Promoting New BT	93
5.3.2	New Products and Companies	95
5.4	Conclusions	97
	References	98
Part Two	The New Paradigm Based on Molecular Biology and Genetics	101
6	Broadening of Biotechnology through Understanding Life, Genetics and Evolution	103
	References	105

7	The Beginnings of the New Biotechnology	107
7.1	Introduction	107
7.2	The Beginnings of Evolution Theory and Genetics	109
7.2.1	Robust Cultures barely Addressed in Biotechnology	111
7.3	The Origin of Recombinant DNA Technology	113
7.3.1	The Cradle of Gene Cloning: Bacterial and Bacteriophage Genetics	113
7.3.2	Antibiotic Resistance in Hospitals: Genetic Flux in Plasmids	114
7.3.3	‘Restriction and Modification’: Finding the Enzymatic Tools for DNA Recombination	115
7.3.4	Gel Electrophoresis for DNA Analysis and Isolation of Specific Fragments	116
7.3.5	‘Handling DNA’	118
7.3.6	New Tools to Study Single Molecules	119
7.3.7	The First Recombinant DNA Experiments	120
7.3.8	DNA Sequence and Recognizing Genes and Gene Function	122
7.3.9	Cloning Larger DNA Fragments	122
7.3.10	Further Tools for the Assembly of Physical Genome Maps	123
7.3.11	Uniting Fragment, Sequence and Chromosome Maps	124
7.3.12	Understanding Gene Regulation in Eukaryotes: A Branch of Reverse Genetics	127
7.4	Oligonucleotide Synthesis Leads to Protein Engineering	127
7.4.1	Chemical Synthesis of Macromolecules: Peptides and Oligonucleotides	130
7.4.2	Combining Chemistry and Biology to Develop Novel Pharmaceuticals	133
7.4.3	Biotechnology’s Competitor: Cheaper Chemical Synthesis	133
7.4.4	‘Muteins’ and the Beginning of Protein Engineering	134
7.5	Synthetic DNA, Reverse Transcriptase: Isolating Genes	136
7.5.1	Reverse Genetics: Providing Cheap Renewable Resources for ‘Germ-Free’ Products	139
7.5.2	Gene Cloning contributes to the Discovery of and Characterization of New Viral Pathogens: Risk Prevention for Biotechnological Products	141
7.5.3	1979–1990: A Rapid Advance in Characterizing Viral Agents	141
7.5.4	Sera and Antivirals: Biotechnological Products in their Own Right	142
7.5.5	Gene Cloning and Production of Pure Material to Characterize Activity: ‘second Generation Products’	143
7.5.6	Enzymes for Replacement Therapy	144
7.5.7	The Emergence of the ‘New Biotech’ Industry	145
7.5.8	‘Third Generation’ Products and the ‘Post-Gene Cloning’ Era	146
7.6	Biodiversity and Gene Mining	147
7.6.1	Recognizing Groups within Biological Diversity	147
7.6.2	Knowledge of Microbial Diversity was Limited by the Lack of Pure Cultures	147
7.6.3	How Much Diversity is There?	148

7.6.4	Genetic Diversity can be studied by Sequencing Microbial, Organelle and Viral Genomes	148
7.6.5	Microbial Genome Analysis and Bioinformatics to Identify Druggable Targets	150
7.6.6	Recognizing and Utilizing Useful Functional Diversity	150
7.6.7	Functional Screening of ‘Shotgun’ and Metagenomic Libraries	153
7.6.8	Entire Genome Sequence of Microbes of Special Interest	155
7.6.9	‘Gene Mining’ Commercialization and Terminology	156
7.6.10	Dealing with the Data Flux	158
7.7	Creating New Diversity by Design or Empirically	160
7.7.1	Limitations in Predicting Protein Structure and Function	160
7.7.2	Genetic Recombination to Create New Assortments of Gene Fragments: PCR	161
7.8	‘Genetic Fingerprinting’	161
7.9	Inherited Predisposition to Disease	164
7.9.1	Heritable Factors Affecting Probabilities of Developing Disease: Predisposition	165
7.9.2	Services for Genome Analysis as Part of Personal Medicine	166
	References	166

8 Ethical Aspects Related to Genome Research, and Reproductive Medicine 171

8.1	Negative Public Reaction to Gene Technology	171
8.1.1	Initial Lack of Acceptance for Gene Technology in Europe	173
8.1.2	International Scientists’ Concerns Led to Guidelines for Gene Cloning	174
8.1.3	Towards a Solution: Increase Scientists’ Involvement in Technology Assessment	176
8.2	Ethical Aspects: Animal Cloning and Fertility Research	177
8.2.1	The Origin of Cloning Animals	178
8.2.2	An Example of Cloning in Animal Husbandry	179
	References	179

9 Elucidating Protein Structure: The Beginnings of Rational Protein Design 181

9.1	Cambridge England, the Cradle of Structural Analysis of Macromolecules	181
9.1.1	Using Knowledge of Structure for Protein Design	182
9.2	Redesigning the Protein Core	184
9.3	Redesigning the Protein by Altering Primary Sequence	184
9.3.1	Multimer States	184
9.3.2	Solubility and Stability	184
9.3.3	Selectivity and Potency	185
9.3.4	Consensus or Combinatorial Products of Natural Gene Products	185
9.3.5	Protein Fusions	185

9.3.6	Protein Truncations	185
9.4	Post Translational Modifications	186
9.4.1	Glycosylation	186
9.4.2	PEGylation	187
9.4.3	HESylation: An Alternative to PEGylation	187
9.4.4	An Alternative to Post-Translational Modification?	188
9.5	Total Chemical Synthesis	189
9.6	Validation of Drug Design Based on the known Structure of the Target	190
9.7	General Considerations in Drug Development	191
9.7.1	rDNA Technology: Yields an Altered Drug Development Paradigm	191
9.7.2	Recombinant DNA has Generated Novel Biotech Products over the Last Decade	192
9.7.3	The Complex Factors (ADMET) Important for Pharmaceutical Drug Development	193
9.7.4	The Problem of Antigenicity	193
9.7.5	Improving Drug Screening	193
9.7.6	High Information Preclinical Screening	194
9.7.7	Animal Models	194
9.7.8	Animal Models to Identify Targets for Human Hereditary Disease	194
9.7.9	Biomarkers: The New Buzz Word in Clinical Screening	195
	References	195
10	The Development of Antibodies as Pharmaceutical Products	197
10.1	An Introduction to the Immune System	197
10.2	The Beginnings of Applied Immunology	198
10.2.1	The Origin of Vaccination	198
10.2.2	Pure Culture, the Beginnings of Microbiological Science Leading to Production of Vaccines	199
10.3	Monoclonal Antibodies	199
10.3.1	A Critical Mass of Intellect and Technology Forms the Cradle for Monoclonal Antibodies	199
10.3.2	High Specificity and Sensitivity of Antigen Detection	200
10.3.3	The Antibody Molecule	201
10.3.4	rDNA Monoclonals: Reproducible Tools for the Life Sciences	201
10.3.5	Selection of Antibodies from Combinatorial 'Display' Libraries	201
10.3.6	<i>In Vitro</i> Selection for Novel Monoclonal Antibodies	202
10.3.7	Transgenic Mice with a Human Immunoglobulin System	203
10.3.8	Antibody Classes and Antibody Functionality	203
10.3.9	A Summary of the Cell Biology in the Generation and 'Evolution' of a Natural Antibody	203
10.3.10	Combinatorial Display Mimics Natural Antibody Generation and Maturation	205
10.4	Producing Antibodies via rDNA and Combinatorial Biology	205

10.5	Affinity Enrichment on Surfaces of Immobilized Target Molecules	207
10.5.1	Other 'Display' Scaffolds; Peptides to Knottins	208
10.5.2	Fusion to other Minor Coat Proteins	209
10.5.3	Combinatorial Library Affinity Selection: Alternatives to Phage Display	209
10.5.4	Pros and Cons of Microbial versus Animal Cell Systems for Selection and Production	210
10.6	Mice with Human Antibody Gene Repertoires	211
10.7	Two Severe Setbacks during Clinical Testing	212
10.8	A Survey of Therapeutic Antibodies	218
	References	220

11 Hereditary Disease and Human Genome Analysis 221

11.1	Introduction	221
11.2	Heredity Studies and Family Counselling	221
11.2.1	The Beginnings of the Study of Hereditary Factors: Altered Proteins	222
11.2.2	Predisposition for Disease: Quantitative Traits	223
11.2.3	The Concept of a DNA-based Physical Map of the Entire Human Genome, about 1980	223
11.2.4	Prenatal Diagnosis	224
11.2.5	Pre-implantation Diagnosis	224
11.3	Early Attempts to Analyse the Human Genome	225
11.3.1	Human Geneticists give Meaning to the Physical Map	226
11.3.2	Organizing (and Funding) the Genome Effort	226
11.4	The Personalized Genome and Personal Medicine	226
11.4.1	DNA CHIP Technology and Haplotype Mapping	226
11.4.2	High-throughput Screening	227
11.4.3	Ordered Micro-arrays and DNA-CHIPS	228
11.4.4	Scannable Random Arrays: Basis for a New Generation of DNA Sequencing	229
11.4.5	DNA CHIPS for Pharmacogenetics and Cancer Diagnostics	230
11.4.6	Analysis of Complex Systems in Personal Medicine	233
11.5	Analysing the Effect of the Environment on the Human Genome: Epigenetics	233
	References	234

12 Transgenic Animals and Plants 235

12.1	Introduction	235
12.2	Stem Cells and Gene Targeting	236
12.2.1	Selective Gene Markers for Animal Cells	236
12.2.2	Site-Specific DNA Mutation	237
12.2.3	Microinjection into the Cell Nucleus	238
12.2.4	Altered Embryonic Stem Cells	238

12.2.5	Transgenic Animals from Engineered ES Cells Injected Into Early Embryos (Blastula)	239
12.2.6	Specific Gene Alterations in Animals	239
12.2.7	Study of Gene Functionality in Transgenic Animals with Conditionally Induced Genes	239
12.2.8	Multicoloured Fluorescent 'Tags' to Analyse Complex Tissue Development	240
12.2.9	Transgenic Model Organisms: A Tool for Biotechnological Development	241
12.2.10	A New Type of Biotechnology Company Based on Transgenics	242
12.2.11	Tackling a New Problem Where Cancer Potential is Sequestered as Stem Cells	242
12.2.12	Vertebrate Clones from Somatic Cells: The Origin in Transplantation of the Cell Nucleus	243
12.2.13	Advances in Fertility Research	243
12.2.14	In Vitro Fertilization and the 'Test Tube Baby'	244
12.2.15	Prenatal and Pre-implantation Diagnosis	244
12.2.16	Animal Clones and Accelerated Breeding	244
12.2.17	Creating Totipotent Cells with Somatic Cell Nuclei: The Breakthrough for Transgenic Animal Cloning	245
	References	245
13	Extrapolating to the Future	247
13.1	Summary of the Status Quo	247
13.1.1	Where are the Novel Tools and Interdisciplinary Studies Taking Us?	247
13.1.2	Understanding the Whole	248
13.2	Insect Control Through 'Sterile' Males (SIT)	248
13.3	The Future of Gene Therapy	249
13.3.1	Slow Progress of Somatic Cell Gene Therapy	249
13.3.2	Germ-Line Therapy	250
13.4	Stem Cell Therapy	250
13.4.1	An Alternative to Human Embryos as a Source of Pluripotent Stem Cells	250
13.4.2	Vectors for Re-programming Somatic Cells to Become Stem Cells	253
13.4.3	A Revolution in Regenerative Medicine	254
13.5	Flash Sequencing DNA: A Human Genome Sequence in Minutes?	255
13.5.1	Another Aspect of Personal Medicine becomes a Reality	256
13.5.2	Terrasequencing: Stimulating Development of Biotechnology and Molecular Medicine	257
13.6	Systems Biology and Looking for 'Druggable' Targets	257
13.6.1	Understanding Mechanisms of Action and Finding 'Druggable' Targets	257
13.6.2	Industrial Acceptance of Systems Biology	258

13.6.3	Estimated Number of Potential ‘Druggable’ Targets	259
13.6.4	Target Modulation rather than ‘On/Off’ Agonist Antagonist Effectors	259
13.7	Synthetic Biology	260
13.7.1	Engineered and Synthetic Organisms	261
13.7.2	Synthetic Genomes and Minimal Organisms	261
13.7.3	Generation of a Bacterium with a Completely Synthetic Genome	262
13.7.4	Organisms with Alternative Genetic Codes	263
13.7.5	Understanding other Structural Complexities in the Cell	263
13.7.6	Gene Mining Meets Synthetic Biology	263
13.7.7	Synthetic Biology: The New Metabolic Engineering	264
13.7.8	RNA Machines: Real Genetic Engineering	264
13.7.9	Summing up Synthetic Biology	266
	References	267

14 Biotechnology and Intellectual Property 269

14.1	Introduction	269
14.2	Patents Ensure Growth and Rapid Dissemination of Knowledge	269
14.3	Owning a Patent does not simply Mean that it can be Implemented: ‘Freedom to Operate’ (FTO)	270
14.3.1	Patent Disputes Drive Licence Exchanges and/or Mergers	270
14.3.2	Critical Timing for Biotech Cooperations	270
14.3.3	Orphan Drugs: Special Status Under Patent Law	271
14.3.4	The Patentability of Inventions Relating to Plants and Animals (Europe)	271
14.3.5	The Patentability of Inventions Relating to Elements Isolated from the Human Body	272
14.4	Life-forms as ‘Novel Subject Matter’ for Patents?	272
14.4.1	General Considerations Relating to Biotechnology Patents	273
14.5	Technology ‘State of the Art’: Precedence/Directives, not Fixed by Law	274
14.5.1	Conflict with Moral Codes	274
14.6	Who can make Decisions about Public Morality?	274
14.7	Biotechnology-orientated Directives Guide Patenting Decisions	275
	References	275

Part Three Application 277

15 Bioprocess Engineering 279

15.1	Introduction	279
15.2	Aspects of Applied Microbiology	280
15.3	Biocatalysis	284
15.4	Biochemical Engineering	287
15.5	Process Sustainability and Ecological Considerations	294
15.6	Biosystems Engineering, including Omics Technologies	296

15.7	Outlook and Perspectives	313
	References	315
16	Industrial Biotechnology	321
16.1	Introduction	321
16.2	General Aspects	323
16.2.1	Raw Materials, Resources	323
16.2.2	Biorefineries	326
16.3	Commodities	328
16.3.1	Biofuels	328
16.3.1.1	Processing	329
16.3.1.2	Future Developments and Challenges	332
16.3.2	Biogas, Energy	334
16.4	Chemicals	336
16.4.1	Bulk Products	336
16.4.1.1	Amino Acids	338
16.4.1.2	Organic Acids	339
16.4.1.3	Vitamins	341
16.4.2	Biopolymers	341
16.4.3	Fine Chemicals – Biotransformations and Chiral Synthons	343
16.4.3.1	Oxidoreductases	345
16.4.3.2	Transferases	349
16.4.3.3	Hydrolases	349
16.4.3.4	Lyases and Synthetases, Hydratases	350
16.4.3.5	Outlook	350
16.5	Food Processing and Products	351
16.6	Environmental Processes	355
16.6.1	Aerobic Waste Water Treatment	357
16.6.2	Anaerobic Waste Water Treatment	358
16.6.3	Exhaust Gas Purification and Further Techniques	359
16.7	Summary, Trends and Perspectives	362
	References	363
17	Pharmaceutical Biotechnology	373
17.1	Introduction	373
17.2	Drug Targeting, Discovery Strategies and Development	375
17.2.1	Discovery Strategies	375
17.2.2	Approval Procedure	377
17.2.3	The Case of Epoprostenol – The Story of a Hit	378
17.3	Pharmaceuticals Production	380
17.3.1	Microbial Fermentation	381
17.3.2	Mammalian Cell Culture – Principles	383
17.4	Products, Pharmaceuticals Made by Biotechnology	387
17.4.1	Low Molecular Weight Agents: Antibiotics, Steroid Biotransformation	389

17.4.1.1	Antibiotics	389
17.4.1.2	Steroid Biotransformation	395
17.4.2	Recombinant Proteins	395
17.4.2.1	Blood Factors and Thrombolytics	398
17.4.2.2	Cytokines, Interferons (IFNs) and Interleukins (ILs)	398
17.4.2.3	Insulin	399
17.4.2.4	Additional Recombinant Hormones	400
17.4.2.5	Monoclonal Antibody (mAb)-Based Products	401
17.4.2.6	Vaccines	401
17.4.3	Further Biopharmaceuticals	402
17.5	Medicinal Techniques, Diagnostics	403
17.5.1	Data Banks, Collections	403
17.5.2	Diagnostic Enzymes and Antibodies	404
17.5.3	Pharmacokinetics, Controlled Release and Drug Targeting	404
17.6	Business: Companies and Economic Aspects	406
17.6.1	General Overview	406
17.6.2	Companies	407
17.6.3	Mergers, Acquisitions, Alliances and Cooperation	409
17.6.4	Conclusions and Future Prospects	411
	References	412

18 Plant Biotechnology 419

18.1	Introduction	419
18.2	Political, Ethical and Biosafety Aspects	420
18.2.1	Political and Ethical Aspects, Patenting	420
18.2.2	Risks and Environmental Aspects	423
18.2.3	Regulations	425
18.2.4	Consumer Acceptance and Public Perception	426
18.3	Research and Development	427
18.3.1	General Principles, Methods	427
18.3.2	Whole Plants and Crop Protection	430
18.3.2.1	Crop Yield and Quality	430
18.3.2.2	Herbicide-Tolerance	434
18.3.2.3	Disease Resistance	436
18.3.3	Products of Primary Metabolism	439
18.3.4	Products of Secondary Metabolism	441
18.4	Application of Modified Plants and Products	444
18.5	Economic Aspects	447
18.6	Summary and Outlook	449
	References	450

Index 455

Preface

Over the last century the development of *Biotechnology* (BT) has followed fascinating pathways to influence ever more aspects of our lives and to provide significant contributions to the improvement of the quality of life. BT flourished in parallel with biological sciences as a result of insights into the molecular details of genetics and the control of biochemical reactions. Following a long-standing tradition, this knowledge was translated by commercial application for human benefit. It enabled biological pathways to be manipulated and even created for the purpose of manufacturing products and developing processes and services on an industrial scale. Historically, controlled fermentation was used to provide efficient storage for food thus enabling a population to survive periods of cold or drought. By the end of the last century biotechnology had developed into a science and engineering discipline in its own right and is considered to be a field of industrial activity with major economic relevance. The applications of BT extend beyond historical tradition, ranging from production of chemicals, bio-fuels and pharmaceuticals to ensuring a continued supply of clean water.

This book reviews the progress of biotechnology over time and highlights the seminal events in this field. It gives an introduction to the main developments, the principles or concepts, and key researchers involved in pioneering work and in conclusion, attempts to extrapolate to further advances expected in the near future. In view of the extensive range of biotechnological activities it was necessary to concentrate on essentials, illustrated with selected examples, as opposed to using an encyclopedic approach. This book is intended to guide the reader through the diverse fields of activity in BT and encourage further reading in the form of books, specialised reviews and original literature as provided in the reference sections. It is envisaged that the readership of this book will include students of biology, biotechnology and biochemical engineering, in addition to scientists and engineers already engaged in or proposing to work in the fields of BT and related disciplines. It may also serve as a broad introduction to BT for other readers who are interested in an overview of the subject, ranging from historical aspects to the latest developments which are largely a result of the accelerated research in molecular biology and bioinformatics that has taken place over the last 20 years.

The *historical aspects* of BT are discussed in the opening chapters which highlight the role of inquisitiveness and the thirst for knowledge and understanding of natural processes. This involves a discussion of reputation-building, the interplay of economics and business as well as the role of and dependence on theories. We trace the developments in chemistry and physics that became a prerequisite for the study of the chemical nature of the components involved in biological processes such as brewing, wine and bread making. Heated discussions centring on both the vitalist and chemical theories resulted not only in the emergence of theories and paradigms but also in their reversal. The close interaction of scientists, craftsmen and industry together with significant stimulus, promoted continued research.

Pasteur and Koch established the science of microbiology. A few decades later Buchner finally refuted the last metaphysical hypothesis that processes in living cells required a 'vis vitalis', a vital factor and following this biochemistry emerged as a new speciality. Biotechnological engineering was based on more precise control of the microbial fermentations involved in food processing including large-scale processes for the manufacture of beer, wine, cheese, bread etc. together with the use of sterile starting materials. This led to the subsequent production of fuels and chemical components for polymers and explosives particularly during war time, and the manufacture of antibiotics and vaccines. This in turn stimulated detailed studies on the manufacture of products from microbial fermentations. By the mid-twentieth century, biotechnology had become an accepted speciality.

Basic research in *biochemistry*, *molecular biology* and *genetics* dramatically broadened the field of life sciences and at the same time unified them by the study of genes and their relatedness throughout the evolutionary process. In Part 2 we discuss the development of this fruitful interplay and describe how it broadened the scope of accessible products and services, at the same time making production cheaper, safer, more reproducible and more reliable. Rapid acceleration of gene and protein analysis caused an explosion of data which led to the emergence of *bioinformatics*. This opened up new avenues for medical analysis that was orientated more towards preventive measures rather than corrective intervention. This is a continuing trend which is substantiated by the prediction that during the next few years affordable analysis of the complete genetic potential of an individual will be available within hours. New areas of research have evolved such as *systems biology* in which living systems can be successfully modelled as networks of ever-increasing complexity. As the volume of information increases and modelling improves so does the probability that insight into potential targets for pharmaceuticals can be better translated into developing successful medicines. To foster such aims, centres for translational medicine are being founded in many cities where medical schools and hospitals participate in close interactions with basic research institutes.

The understanding of the fundamental *programming of animal cells* in the developing embryo and in particular the discovery of a small number of proteins capable of guiding stem cell differentiation and even the reprogramming of already differentiated cells, has opened up perspectives for a completely new and very exciting branch of biotechnology in the area of tissue and organ synthesis for *regenerative medicine*. In combination with advances in fertility medicine this has also led to the

cloning of animals and the production of *transgenic animals*. One aspect of this technology is the use of tissue cloning to produce human tissue cultures as models for inherited disease.

In Part 3 we discuss engineering and applied topics. *Biochemical and bioprocess engineering* constitute the basis for translating scientific innovation and development into industrial processes. They represent an interdisciplinary field based on molecular biology, biochemistry and engineering disciplines. As a result of the progress in molecular biology, new tools known as the ‘omics’ were developed: genomics, proteomics and metabolomics, to mention only the most common. *Biosystems engineering* or systems biotechnology, integrates the approaches and the extensive volume of data derived from these specialities and from bioreaction engineering in a ‘holistic’ approach, using bioinformatics tools.

Industrial biotechnology, with its historical roots, continues in diverse industrial fields of activity including food and feed and commodities such as enzymes for use in detergents, bio-fuel and energy production, polymer manufacture and the development and production of many drug constituents, as well as providing services, for example in waste treatment and other processes related to environmental protection.

The approval in 1982 of recombinant human insulin produced in *E. coli* and developed by Genentech in cooperation with Eli Lilly in the late 1970s, was an historical landmark. By 2006, some 165 biopharmaceuticals had been approved in the EU and/or the USA for human use. This illustrates the emergence and rise of recombinant technologies which constitute the basis of *pharmaceutical biotechnology*. Today, approximately one in four of all genuinely new drugs currently entering the market is a biopharmaceutical and in 2008 over 400 biopharmaceuticals were in various stages of clinical evaluation. These include hormones, soluble hormone receptors (as hormone antagonists), blood factors, thrombolytics, interferons, monoclonal antibodies, vaccines and therapeutic enzymes. Selected aspects of engineering and production processes together with information relating to their use are discussed in this chapter. Data on industrial development, products, companies and economics are also presented.

The potential of transgenic *plant biotechnology* is to create crops that produce higher yields and are able to grow on less fertile land in order to feed the growing world population. Crops should be resistant to pests and require less chemical treatment, notably with insecticides, fungicides, herbicides and fertilizers, and exhibit low environmental impact. The majority of agricultural scientists are convinced that such crops can be delivered by the exploitation of molecular breeding strategies. Food production has risen considerably over the decades in terms of a ‘Green Revolution’, most notably in developing countries, but the increase in per capita food supply has been small. Hence research in recombinant food production is considered to be a necessary part of the strategies to ensure adequate nutrition. Nevertheless, debates over the risks of the technology have evoked conflicts and created a critical, even negative publicity, particularly in Western Europe.

BT offers in general a sustainable method of production, based mostly on renewable resources with minimal or no waste and by-products that can be recycled or reused, for example as feed components. There are manifold interactions with

political, social, economic and environmental issues. Laws, regulations and ethical concerns pertinent to biotechnology are important topics of discussion although there are dramatic differences in legislation between countries. Current efforts are centred around establishing common global regulations including the removal of unfair unilateral advantages and support for health care and economies in developing countries. The regulatory influences which affect how science is carried out and technology is applied are addressed in each chapter. In addition to the underlying scientific concepts, further information is presented in each chapter on the use of products, along with data on industrial activities and production.

The increase in computing power due to the invention and continued development of microchips via nanotechnology has pioneered and driven a revolution in communication during the last three decades. At least one computer, television and mobile telephone have found their place in essentially every home. Biotechnology has also undergone a corresponding development, although perhaps not so immediately identifiable at the level of consumer goods in the shops. There is, however, hardly an area of human activity which has not been affected by the recent biotechnological revolution. We hope that after completing our book, the readers will feel that they have a better understanding of how and why this revolution took place, its roots and its further potential to improve so many aspects of our lives.

Acknowledgements

We are most grateful for comments on the manuscript from a number of friends and colleagues as well others who agreed to have their photographs taken for inclusion in the book. Their comments contributed to the readability of the text, led to the avoidance of certain errors and extended the knowledge base. We, the authors take full responsibility for any remaining mistakes.

In particular thanks are due to Anthony (Tony) C. R. Samson, Karl Simpson, Raimo Franke, Heidi Lloyd-Price, and Erik Pollmann, Ulrich Behrendt, Sonja Berensmeier and Volker Kasche for significant information and relevant advice.

Further valuable information and assistance was contributed by Robert Bud, Arnold Demain, Albert J. Driesel, Reinhard Hehl, Dietmar Hempel, Gerhard Höfle, Hans-Joachim Jördening, Peter Rapp, Jürgen Seibel and Hermann Stegemann. We would also like to thank Frank Weinreich for his wise suggestions during the final stages of converting our manuscript into a book. JC is grateful to the Helmholtz Centre for Infection Research, Braunschweig (HZI; formerly the GBF) for funding the transport costs to international meetings.

This book is dedicated to our wives Diana Buchholz and Marie-Christiane Collins without whose support we could not have completed this project.

Abbreviations and Glossary

Acre	4046 m ²
ADM	Archer Daniels Midland (starch producing and converting company, USA)
ADP	adenosine diphosphate
7-ACA	7-Aminocephalosporanic acid
7-ADCA	7-Aminodesoxycephalosporanic acid
6-APA	6-Aminopenicillanic acid
AIChE	American Institute of Chemical Engineers
AMP	adenosine monophosphate
Array CGH	<i>Array Comparative Genome Hybridization</i> , for example for comparing (malignant) biopsy material with DNA from normal tissue
ATP	adenosine triphosphate
BAC libraries (BACs)	bacterial artificial chromosome libraries
BHK	baby hamster kidney (cells)
BMP	bone morphogenetic protein
BMS	Bristol Meyers Squibb (USA)
bn	billion
BOD	Biological oxygen demand (of waster water)
BP	Before present
BPTI	Bovine pancreatic trypsin inhibitor
BT	Biotechnology
Bt	<i>Bacillus thuringiensis</i>
C&EN	Chem. Eng. News
CCD	computational cell dynamics
cDNA	copy DNA, reverse transcribed from mRNA
CDR	complementarity-determining region of an antibody
CEPH	Centre d'études des polymorphismes humains, Paris, France (The Centre for the Study of Human Polymorphisms)
CFD	computational fluid dynamics
CFTR	Cystic fibrosis transmembrane conductance regulator
cGMP	current Good Manufacturing Practice

CHO	Chinese hamster ovary (cells)
CIP	clean in place
CMV	Cytomegalie virus
CNV	copy number variation
CP	capsid or coat protein (of virus)
CSF	Colony stimulating factor
Cultivars	cultivated plant varieties
2D	two dimensional
DARPs	Designed Ankyrin Repeat Proteins
2DE	two dimensional electrophoresis
2DE IEF/SDS-PAGE	two dimensional electrophoresis combined with IEF and SDS-PAGE
DGT	direct gene transfer (including particle bombardment)
DHA	docosahexanoic acid
dm	dry matter
2D-PAGE	two-dimensional gel electrophoresis
2DE IEF/SDS-PAGE	two dimensional electrophoresis method
DH	dehydrogenase
DOE US	Department of Energy, United States of America
DPN ⁺	diphosphonucleotide (is identical with NAD ⁺)
DPNH	hydrogenated diphosphonucleotide (is identical with NADH)
dt/ha	decitonnes (0,1 t) per hectare
€	EURO, 1.40 \$ (Oct. 2010, mean)
EBIT	earnings before interest and taxes
E. coli	<i>Escherichia coli</i>
EF	environmental factor
EI	environmental index
ELISA	enzyme linked immunosorbent assay
EMA	European authority for approval of pharmaceuticals
EP	epothilone
EPA	Environmental Protection Agency (USA)
EPA	eicosapentanoic acid
Epitope	specific region on a protein recognized by an antibody
EPC	European patent convention (5 October 1973)
EPO	European patent office or Erythropoietin
ER	endoplasmatic reticulum
ESC or ES	embryonic stem cells
ESI-MS	electrospray-ionisation mass spectrometry
ESI-TOF MS/MS	electrospray-time of flight-mass spectrometry
EST	expressed sequence tags; short DNA fragments obtained by random sequencing of clones from cDNA libraries
EU	European Union
FAO	Food and Agriculture Organization (USA)
FBA	flux balance analysis

FDA	Food and Drug Administration (USA)
FDP	fructose-1,6-diphosphate
Fluxome	flux distribution of the central metabolic pathways
Ft.	feet (30.5 cm)
Gal	gallon (3,78 L)
GC-MS	coupled gas chromatography-mass spectrometry
GM	genetically modified;
GMO	genetically modified organism
GRAS	generally recognized as safe
GMP	Good Manufacturing Practice
GPCRs	G protein coupled receptors
GSK	GlaxoSmithKline
ha	hectar, 10 000 m ²
hGH	human growth hormone
HIV	Human immunodeficiency virus
hl	hectoliter (100 l)
HR	hypersensitive response
HTS	high throughput screening
IEF	isoelectric focusing
IFN	interferon
IgG	immune globulin G
IL	interleukin
In.	inch (2.54 cm)
i.v.	intravenous
JACS	Journal Am. Chem. Soc.
J&J	Johnson & Johnson
LC-MS	liquid chromatography-mass spectrometry
LD (LOD score)	linkage disequilibrium in population genetics
LRR	leucine-rich-repeat proteins, for example ankyrin
mAB	monoclonal antibody
MALDI-TOF-MS	Matrix-Assisted-Laser-Desorption/Ionization – Time-Of-Flight-Mass-Spectrometry
MDR	multi drug resistant
MFA	metabolic flux analysis
MI	mass Index
miRNAs	micro RNAs
mn	million
Mtoe	million tons oil equivalents
Mw	molecular weight, molar mass
m-Arrays	micro-arrays
NAD	Nicotinamide-adenine-dinucleotide
NADH	hydrogenated NAD
NBF	new BT firm
NCE	new chemical entity
NGOs	non governmental organizations

NIH	National Institutes of Health (USA)
NK cells	natural killer cells
NMR	nuclear magnetic resonance
NRRL	Northern Regional Research Laboratory (USA)
NSO	mouse myeloma derived mammalian cells
ON	oligonucleotides
ORF	open reading frame
OS	oligosaccharides
OTA	Office of Technology Assessment (USA)
PAGE	polyacrylamide gel electrophoresis
PAT	process analytical technology
PDO	1,3-propanediol
PDR	pathogen-derived resistance
PEG	polyethylene glycol
PEGylation	attachment of polyethylene glycol
PET	positron emission tomography
PHB	polyhydroxybutyrate (a polyester)
pI	Ionic strength (logarithmic scale)
Plastids	Intracellular organelles, e.g., chloroplasts that have their own double stranded DNA
pO ₂	oxygen partial pressure
Pound	453 g
PR	pathogenesis related
PR	plant disease resistance
PS	iPS and piPS Pluripotent stem cells, induced pluripotent stem cells, protein-induced pluripotent stem cells
PSTI	Human pancreatic secretory trypsin inhibitor
QTL	quantitative trait locus
QM	quality management
R	resistance (genes)
rasiRNAs	repeat-associated small interfering RNA.s
R&D	research and development
rDNA	recombinant DNA
rDNA technologies	recombinant DNA technologies
rh	recombinant human
RNAi	interfering RNA, RNA interference
rPC	real time PCR
rRNA	ribosomal RNA
\$	US \$, corresponding to 0,71 € (Oct. 2010, mean)
SAGE	serial analysis of gene expression
SDA	stearidonic acid
SDS-PAGE	sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEC	size exclusion chromatography
SIP	sterilization in place
siRNA	small interfering RNA

shRNA	short hairpin RNA
SNP	single nucleotide polymorphism
STR	stirred tank reactor
SUB	single use bioreactor
t/a	tonnes per year
TM	trade mark
TNF	Tumor necrosis factor
tPA	Tissue plasminogen activator
Translation capacity	the number of times a transcript is translated.
USDA	US Department of Agriculture
US\$	US dollar (see \$)
YAC libraries.	yeast artificial chromosome. libraries

Part One

History

